Abstract
Ceftazidime belongs to cephalosporin class of antibiotics with broad spectrum activity. Tobramycin is an aminoglycoside antibiotic used to treat various types of bacterial infections, particularly gram negative infections. Combination therapy of ceftazidime tobramycin is adopted in many clinical conditions. In present study, the authors have tried to determine the comparative antimicrobial activity of ceftazidime, tobramycin and their novel Fixed Dose Combination (FDC) in some pathogenic microorganisms. Minimum Inhibitory Concentration (MIC) and Antibiotic Susceptibility Test (AST) were performed. The AST results show that the FDC of these antibiotics significantly increased zone of inhibition in all microorganisms as compared to individual therapy of ceftazidime and tobramycin. In case of Morganella morganii and Citrobacter freundii, gram negative bacteria, the antimicrobial activity was increased by 3.69% and 5.79% in FDC of these antibiotics when compared tobramycin alone. MIC of FDC of ceftazidime and tobramycin in Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus was much lower in comparison to ceftazidime and tobramycin alone. These results indicate that the FDC of ceftazidime and tobramycin has better bactericidal activity in comparison to ceftazidime and tobramycin alone in organisms under study.
Keywords: Ceftazidime, tobramycin, fixed dose combination, minimum inhibitory concentration
Current Drug Therapy
Title: Comparative Antimicrobial Activity of Ceftazidime, Tobramycin and their Novel Fixed Dose Combination in Some Pathogenic Microorganisms
Volume: 4 Issue: 2
Author(s): Sanjay Mohan Shrivastava, Sanjeev Kumar Shukla, Vivek Kumar Dwivedi and Manu Chaudhary
Affiliation:
Keywords: Ceftazidime, tobramycin, fixed dose combination, minimum inhibitory concentration
Abstract: Ceftazidime belongs to cephalosporin class of antibiotics with broad spectrum activity. Tobramycin is an aminoglycoside antibiotic used to treat various types of bacterial infections, particularly gram negative infections. Combination therapy of ceftazidime tobramycin is adopted in many clinical conditions. In present study, the authors have tried to determine the comparative antimicrobial activity of ceftazidime, tobramycin and their novel Fixed Dose Combination (FDC) in some pathogenic microorganisms. Minimum Inhibitory Concentration (MIC) and Antibiotic Susceptibility Test (AST) were performed. The AST results show that the FDC of these antibiotics significantly increased zone of inhibition in all microorganisms as compared to individual therapy of ceftazidime and tobramycin. In case of Morganella morganii and Citrobacter freundii, gram negative bacteria, the antimicrobial activity was increased by 3.69% and 5.79% in FDC of these antibiotics when compared tobramycin alone. MIC of FDC of ceftazidime and tobramycin in Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus was much lower in comparison to ceftazidime and tobramycin alone. These results indicate that the FDC of ceftazidime and tobramycin has better bactericidal activity in comparison to ceftazidime and tobramycin alone in organisms under study.
Export Options
About this article
Cite this article as:
Shrivastava Mohan Sanjay, Shukla Kumar Sanjeev, Dwivedi Kumar Vivek and Chaudhary Manu, Comparative Antimicrobial Activity of Ceftazidime, Tobramycin and their Novel Fixed Dose Combination in Some Pathogenic Microorganisms, Current Drug Therapy 2009; 4 (2) . https://dx.doi.org/10.2174/157488509788185150
DOI https://dx.doi.org/10.2174/157488509788185150 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adenosine and ATP Receptors in the Brain
Current Topics in Medicinal Chemistry Posaconazole: A New Antifungal Weapon
Reviews on Recent Clinical Trials Vasculogenic and Angiogenic Pathways in Moyamoya Disease
Current Medicinal Chemistry Novel Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Editorial [Hot topic:Targeted Alpha Particle Therapy (Guest Editors: Ganesan Vaidyanathan and Roy Larsen)]
Current Radiopharmaceuticals Neurosarcoidosis
Current Neuropharmacology Novel Kynurenic Acid Analogues in the Treatment of Migraine and Neurodegenerative Disorders: Preclinical Studies and Pharmaceutical Design
Current Pharmaceutical Design A Review of the Potential Receptors of Migraine with a Special Emphasis on CGRP to Develop an Ideal Antimigraine Drug
Current Molecular Pharmacology Hybrid Drugs as Potential Combatants Against Drug-Resistant Microbes: A Review
Current Topics in Medicinal Chemistry Vaccination and Antiviral Treatment of Neglected Diseases Caused by Flaviviral Infections
Current Medicinal Chemistry Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) Antibodies: Can They Protect Against HIV Infection?
Current Drug Targets - Infectious Disorders Nenatal Drug Induced Nephrotoxicity : Old and Next Generation Biomarkers for Early Detection and Management of Neonatal Drug-Induced Nephrotoxicity, with Special Emphasis on uNGAL and on Metabolomics
Current Medicinal Chemistry Natural Products and their (Semi-)Synthetic Forms in the Treatment of Migraine: History and Current Status
Current Medicinal Chemistry New Drugs and Treatment Regimens
Current Respiratory Medicine Reviews New Strategies and Patent Therapeutics in EBV-Associated Diseases
Mini-Reviews in Medicinal Chemistry Preface
Current Drug Targets - Infectious Disorders Newer Cephalosporins are Only Marginal Advancements Over Existing Compounds
Current Medicinal Chemistry - Anti-Infective Agents Porphyromonas gingivalis Mediated Periodontal Disease and Atherosclerosis:Disparate Diseases with Commonalities in Pathogenesis Through TLRs
Current Pharmaceutical Design Targeted α-Particle Therapy: A Clinical Overview
Current Radiopharmaceuticals